We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Pliant Therapeutics Inc
6 own
4 watching
Current Price
$0
$-0.06
(-0.26%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,361.82M
52-Week High
36.64
52-Week Low
6.3701
Average Volume
0.06M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,361.82M52-Week High36.6452-Week Low6.3701Average Volume0.06MDividend Yield--P/E Ratio--What does the Pliant Therapeutics Inc do?
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More
How much money does Pliant Therapeutics Inc make?
News & Events about Pliant Therapeutics Inc.
Globe Newswire
1month ago
FVC Change from Baseline over 24 Weeks: ITT Population | ITT Population- SoC Subgroup
Figure 1. Change in FVC from Baseline of Bexotegrast 320 mg Over 24 Weeks
Figure 2.
Proportion of Patients with FVC Change from Baseline of Bexotegrast 320 mg Over 12 and 24 Weeks versus Placebo - Intent to ...
Globe Newswire
1month ago
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliants President...
InvestorPlace
2 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.
The post 7 Biotech Stocks to Buy for 100% Returns appeared first on InvestorPlace...
Zolmax
2 months ago
Pliant Therapeutics, Inc. (NASDAQ:PLRX Get Rating) CFO Keith Lamont Cummings sold 9,960 shares of the stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $26.52, for a total value of $264,139.20. Following the sale, the chief financial officer now directly owns ...
Zolmax
2 months ago
Pliant Therapeutics, Inc. (NASDAQ:PLRX Get Rating) insider Eric Lefebvre sold 11,245 shares of Pliant Therapeutics stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $26.52, for a total value of $298,217.40. Following the completion of the sale, the insider ...
Frequently Asked Questions
Frequently Asked Questions
What is Pliant Therapeutics Inc share price today?
Can Indians buy Pliant Therapeutics Inc shares?
How can I buy Pliant Therapeutics Inc shares from India?
Can Fractional shares of Pliant Therapeutics Inc be purchased?
What are the documents required to start investing in Pliant Therapeutics Inc stocks?
What is today’s traded volume of Pliant Therapeutics Inc?
What is today’s market capitalisation of Pliant Therapeutics Inc?
What is the 52-Week High and Low Range of Pliant Therapeutics Inc?
What percentage is Pliant Therapeutics Inc down from its 52-Week High?
What percentage is Pliant Therapeutics Inc up from its 52-Week Low?
Current Price
$0
$-0.06
(-0.26%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.